{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:02:59Z","timestamp":1763640179427,"version":"3.37.3"},"reference-count":40,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801832"],"award-info":[{"award-number":["81801832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo","doi-asserted-by":"publisher","award":["2018A610273"],"award-info":[{"award-number":["2018A610273"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Postdoctoral Science Foundation of China","doi-asserted-by":"publisher","award":["2019T120491","2019M625046"],"award-info":[{"award-number":["2019T120491","2019M625046"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Fund of Zhejiang Provincial Education Department","award":["Y201840521"],"award-info":[{"award-number":["Y201840521"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,7,23]]},"DOI":"10.1080\/14656566.2020.1747432","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T12:53:05Z","timestamp":1586350385000},"page":"1311-1318","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes"],"prefix":"10.1080","volume":"21","author":[{"given":"Shujuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhejiang Pharmaceutical College, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Pharmaceutical College, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Pharmaceutical College, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31947-0"},{"key":"cit0002","doi-asserted-by":"crossref","unstructured":"American DiabetesAssociation. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl_1):S61\u2013S70.","DOI":"10.2337\/dc19-S006"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0279"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1177\/1932296814557518"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901051"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212599"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1216-4"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1177\/0145721707312400"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S20633"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819879093"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0228"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001086"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1402"},{"key":"cit0014","unstructured":"Zealand Pharma. Dasiglucagon, a novel glucagon analog phase 2 update. Available from: https:\/\/static1.squarespace.com\/static\/58983777d1758e28995640b4\/t\/5912d3251e5b6cb374772105\/1494405933418\/TIDES"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1021\/bi061228n"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2014.01.006"},{"key":"cit0017","unstructured":"NCT02660008. Single doses of ZP4207 adm. sc to hypoglycemic TD1 pt. to describe the PK and PD of ZP4207 as comp. to marketed glucagon. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660008."},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13562"},{"key":"cit0019","unstructured":"NCT02916251. ZP4207 (dasiglucagon) administered to T1D patients to assess the PK and PD compared to marketed glucagon. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02916251"},{"key":"cit0020","unstructured":"NCT03378635. A trial to confirm the efficacy and safety of dasiglucagon in the treatment of hypoglycemia Type 1 diabetes subjects. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03378635."},{"key":"cit0021","unstructured":"Zealand Pharma. Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia. Available from: http:\/\/hugin.info\/136974\/R\/2195576\/850683.pdf"},{"key":"cit0022","unstructured":"NCT03667053. Trial to confirm the efficacy and safety of dasiglucagon in the treatment of hypoglycemia in T1DM children. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03667053."},{"key":"cit0023","unstructured":"Zealand Pharma. Zealand Pharma achieves primary and all key secondary endpoints in pediatric phase 3 trial with dasiglucagon for severe hypoglycemia. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/b0ed4f03-bf50-4330-8e00-88ecd74ab39f."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00591"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12571"},{"key":"cit0026","volume":"20","author":"Jafri R","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"cit0027","unstructured":"NCT03840278. The bihormonal iLet bionic pancreas feasibility study. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840278."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0363"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121265"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00141-2"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70226-8"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1472"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00334-w"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1159\/000129680"},{"key":"cit0035","unstructured":"Zealand Pharma. Zealand Pharma announces progress to phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018. Available from: http:\/\/hugin.info\/136974\/R\/2162673\/831901.pdf"},{"key":"cit0036","unstructured":"NCT03777176. Open-label trial evaluating efficacy and safety of dasiglucagon in children with congenital hyperinsulinism. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03777176."},{"key":"cit0037","unstructured":"NCT03941236. Extension trial evaluating the long-term safety and efficacy of dasiglucagon in children with congenital hyperinsulinism. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03941236."},{"key":"cit0038","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dci16-0025","volume":"39","author":"Rickels MR","year":"2016","journal-title":"Diabetes Care"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818757795"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816653141"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1747432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:27:29Z","timestamp":1620466049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1747432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,7,23]]}},"alternative-id":["10.1080\/14656566.2020.1747432"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1747432","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}